Big Pharma is worried. The $300 billion brand-name drug
industry could face declines as a flurry of blockbuster drugs introduced in the 1990s--Plavix, Seroquel--lose their 20-year patent protection, allowing manufacturers to offer generic versions.READ»
As CEO of Novartis, Europe's second largest drug company, the former competitive swimmer Joe Jimenez won't rest until he snags the top spot. The key: innovative products, expansion into new markets, and good old-fashioned team building.READ»
Nimbus, a biopharmaceutical company that leverages cloud computing to discover medicines, is working on a lymphoma cure, as well as a fat-burning drug that mimics exercise.READ»
While the standard doctor-pharmacy model is still alive and flourishing throughout the civilized world, an uptick in online drug purchases has prompted the creation of an illegal cottage industry. Welcome to the world of counterfeit drugs, a $200-billion arena of deceit and high-profits.READ»
Transportation is the second largest contributor of CO2 emissions in the U.S.--so if an industry can streamline its distribution network, emissions will probably drop. Enter IBM's effort at fixing the pharmaceutical supply chain.READ»
Originally created by Frederick Fennell at the Eastman School of Music
in Rochester, New York, in 1952 the modern wind ensemble was developed
to feature the full range of woodwind instruments in a concert band
setting. Since then, ...READ»
What is the product-defense industry? How does it work, and who's behind it? We asked David Michaels, author of the exposé Doubt Is Their Product.READ»
In the super-regulated world of pharmaceuticals, some of the world’s largest corporations are using digital media to get closer to customers and advocates. GlaxoSmithKline and Johnson & Johnson are using blogs to engage in ...READ»
